Page 20 - Aurobindo Pharma

Improving margin to up Aurobindo earnings

Even as revenue growth may soften due to high base, rising operating profit margin bodes well for firm

Aurobindo Pharma Q2 net profit up 33% at Rs 605 crore

Company's income from operations grew 12.19% to Rs 3775.45 crore

US FDA gives tentative approval for Aurobindo's generic HIV drug

ViiV Healthcare, Aurobindo Pharma signed an agreement allowing Aurobindo to supply Dolutegravir 50 mg in 92 licensed countries

Aurobindo Pharma gains on tentative nod for HIV drug

The stock up 4% to Rs 842 after the company has received the tentative approval of Dolutegravir 50mg from USFDA for the treatment of HIV.

Aurobindo Pharma plans to launch 19 drugs in US in next 3 quarters

The company has already 20 products in the US market under OTC segment

Aurobindo, Intas seek to boost Europe business with Teva bid

Indian drug makers Aurobindo Pharmaceuticals and Intas are in the race to acquire Teva's generic drugs in Britain as a part of their plans to expand their European businesses

Aurobindo beats the pharma blues

Stock gains 7% as US formulation business growth boosts profit, net debt reduces by $115 million

Aurobindo Pharma gains on strong Q1 results

The stock rallied 6% to Rs 778 after the company reported 24% YoY jump in consolidated net profit at Rs 585 crore in Q1FY17.

Aurobindo Pharma Q1 net profit up 24% at Rs 584 crore

The net profit for the year ago period was Rs 471.3 crore

Aurobindo Pharma to set up vaccine manufacturing facility

It, however, did not disclose information related to location of the manufacturing facility

Aurobindo Pharma gets USFDA nod for anti-infective injection

Company is expected to launch Linezolid injection in the second quarter of the 2016-17

Aurobindo gets ready to play with the big boys

Aurobindo is in a race with two other multinationals for the acquisition of Teva Pharmaceutical's European assets

Aurobindo's anti-cholesterol drug gets USFDA nod

Rosuvastatin Calcium has a market size of $6.7 billion

Aurobindo Pharma gains on USFDA approval for Rosuvastatin calcium tablets

The stock moved higher by 4% to Rs 788 on the BSE.

Aurobindo eyes Teva's products in Europe

The company would reportedly finance the deal with a loan of more than $1 billion

Aurobindo eyes Teva's product sale in Europe

According to Bloomberg, Aurobindo will finance acquisition of 'overlapping drugs' with a loan of $1 billion

Aurobindo Pharma keeps up pace

Product approvals, Natrol drive US growth; European turnaround adds to performance

Aurobindo Pharma to step up product launches in US

The move is crucial to its ambitious goal of seeing $3 billion revenues by FY18

Aurobindo Q4 net up 39% at Rs 563 cr

Company crosses $2 billion revenue mark in FY16

Aurobindo Pharma gains on good Q4 results

The stock was up 5% at Rs 795 on the BSE.